Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients

D. Lorusso, G. Ferrandina, S. Greggi, A. Gadducci, S. Pignata, S. Tateo, R. Biamonte, L. Manzione, G. Di Vagno, F. Ferrau, Giovanni Scambia, G. Garganese, F. Legge, M. Ludovisi, A. Fanucchi, S. Cosio, R. Tambaro, R. V. Iaffaioli, Fondazione G. Pascale, D. GermanoM. Lapresa

Research output: Contribution to journalArticlepeer-review

Abstract

Background: A phase III multicenter randomized trial has been designed in order to address whether amifostine (WR-2721, Ethyol), an organic thiophosphate cytoprotector, can protect ovarian cancer patients from toxicity induced by carboplatin-paclitaxel chemotherapy. Patients and methods: Patients were randomly assigned to receive carboplatin [area under the curve (AUC) 5 mg·min/ml] and paclitaxel (175 mg/m 2) with (arm A) or without (arm B) amifostine (910 mg/m 2) every 21 days for six cycles. Results: One-hundred and eighty-seven patients were accrued: 93 patients in arm A and 94 patients in arm B. There was no difference in terms of erythrocytopenia between the two arms; grade 3-4 thrombocytopenia was higher in arm A (3.3% versus 0.6%; P = 0.0010). There was no significant reduction of grade 3-4 leukopenia in arm A (11.8% versus 13.8%). The incidence of grade 3-4 neutropenia was lower in arm A (31.3% versus 37.9%; P = 0.03), as was the incidence of severe mucositis (4.7% versus 15.4% in arm A versus arm B, respectively; P

Original languageEnglish
Pages (from-to)1086-1093
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 1 2003

Keywords

  • Amifostine
  • Carboplatin
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients'. Together they form a unique fingerprint.

Cite this